Altre lingue Actinogen Medical Limited

Azioni

ACW

AU000000ACW3

Mercato chiuso - Australian S.E. Altri mercati azionari 08:10:24 12/07/2024			Variaz. 5gg	Var. 1 gen.
0,071 ^AUD	-4,05%		+9,23%	+222,73%

02/07	Actinogen Medical si aspetta i risultati dello studio clinico di fase 2a di XanaCIDD in agosto; le azioni scendono del 6%.	MT
26/06	Actinogen Medical Limited annuncia la pubblicazione con revisione paritaria del suo biomarcatore di fase 2a	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Actinogen Medical Expects Results from XanaCIDD Phase 2a Clinical Trial in August; Shares Down 6%	02/07
Actinogen Medical Limited Announces the Peer-Reviewed Publication of its Phase 2a Biomarker	26/06
Actinogen Medical's Xanamem Drug 'Potentially Slows' Progression of Alzheimer's Disease	26/06
Actinogen Medical Completes AU$3.9 Million Non-Renounceable Entitlement Offer	30/05
Actinogen Medical Opens AU$3.9 Million Entitlement Offer; Shares Down 7%	15/05
Actinogen Medical Lodges Prospectus for Nearly AU$4 Million Entitlement Offer	07/05
Actinogen Medical Raising Up to AU$8.9 Million for Advancing Trial, Working Capital; Shares Fall 24%	03/05
Actinogen Medical Limited Announces the Full Enrolment of 167 Participants in the Company's XanaCIDD Phase 2A Clinical Trial in Patients with Cognitive Importive in Major Depressant Disorder	22/04
Actinogen Medical Completes Patient Enrolment for XanaCIDD Phase 2a Trial; Shares Up 3%	22/04
Actinogen Medical Limited Announces First Patient Treated in XanaMIA Phase 2b Alzheimer's Disease Trial	15/04
Actinogen Doses First Patient in Phase 2b Alzheimer’s Disease Trial; Shares Rally 16%	15/04
Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation	25/03
Actinogen Medical Initiates Final Enrolment Phase for XanaCIDD Depression Trial; Shares Rise 3%	07/03
Actinogen Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023	25/02
Actinogen Medical Secures UK Innovation Passport for Alzheimer’s Disease Treatment	15/02
Actinogen Medical Activates First Trial Site for Phase 2B Alzheimer’s Disease Trial	20/12
Actinogen Medical Limited Announces Enrolment in the XanaCIDD Phase 2A Proof-Of-Concept Trial	28/11
Actinogen Medical's XanaCIDD Trial Enrolment Surpasses 50% Milestone	28/11
Actinogen Medical Receives AU$4.8 Million R&D Tax Refund	28/11
Actinogen Medical Names CFO	08/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Actinogen Medical Limited

Azioni

ACW

AU000000ACW3

Altre lingue

Filtri